Designing a Study of Correlates of Risk for Ebola Vaccination. Issue 8 (23rd January 2020)

• Record Type: Journal Article
• Authors: Halloran, M Elizabeth; Longini, Ira M; Gilbert, Peter B
• Is Part Of: American journal of epidemiology. Volume 189:Issue 8(2020)
• Page Start: 747
• Page End: 754
• Publication Date: 2020-01-23
• Subjects: case-cohort design -- correlates of risk -- Ebola virus vaccine -- immune response biomarkers -- ring vaccination; Epidemiology -- Periodicals; Public health -- Periodicals; 614.4
• DOI: 10.1093/aje/kwaa001
• Languages: English
• ISSNs: 0002-9262

Abstract

Abstract: The recombinant vesicular stomatitis virus (rVSV) Ebola vaccine was shown to be very efficacious in a novel ring vaccination trial in Guinea. However, no correlates of vaccine protection have been established for Ebola vaccines. Several Ebola vaccine candidates are available, but conducting randomized trials of additional candidates in outbreaks is difficult. Establishing correlates of vaccine protection is essential. Here we explore power and sample-size calculations to evaluate potential correlates of risk during an Ebola vaccination campaign in an outbreak. The method requires that a blood draw be made at a predetermined time after vaccination. The statistical analysis estimates the relative risk of the Ebola endpoint occurring from after the blood draw through to the end of follow-up, contrasting vaccine recipients with different values of the immune response marker. The analysis can be done assuming a trichotomous or continuous marker. Under certain assumptions, at an overall vaccine efficacy of 75%, 50 Ebola endpoints in the vaccinees provided good power. At an overall vaccine efficacy of 90%, 20 Ebola endpoints gave good power. Power was highest when more vaccinees were in the high- and low-responder groups versus the middle group and when vaccine efficacy differed the most between the high- and low-responder groups.